20241029-华鑫证券-博雅生物-300294.SZ-公司事件点评报告_血制品保持稳健增长_内生外延助力浆站拓展_5页_227kb

As of the end of October 2024, Biovail Pharmaceutical Group (SZ300294) maintained steady growth in its blood products business, driven by both internal development and external acquisitions. Despite a significant decline in overall revenue due to asset sales in 2023 (a 39% decrease in 2023A), the blood products segment grew by 0.39% year-over-year from January to September 2024. The company expanded its plasma collection to 38,744 tons, marking a 123.9% increase, supporting future growth through new stations and the recent acquisition of Grex Cross China.

Key highlights include:

1. Market Position: Biovail remains a leader in Chinese blood products, with diverse products and steady revenue growth in its plasma-derived medicines.

2. Innovation Pipeline: The company has multiple innovative drugs in development, including recombinant factor VIII and an investigational high-concentration IVIG formulation, aiming for enhanced differentiation.

3. Acquisition Strategy: An acquisition of Grex Cross China bolstered the company's operations, strengthening its market position and potentially attracting international collaborations.

4. Valuation and Outlook: Biovail's current valuation is attractive with a target P/E ratio of under 25x 2026 estimates. We maintain our "Buy" recommendation, emphasizing the company's resilient operations, strong fundamentals, and potential for sustained growth.

Overall, Biovail’s combination of robust revenue growth, strategic acquisitions, and a rich pipeline positions the company as a key player in China’s blood product sector, with significant upside potential for investors seeking exposure to this vital healthcare industry.